Contact

Phone: +1 403 910 5140
Email: info@willowbio.com

Follow us
Willow Biosciences white W logo.

© 2022 Willow Biosciences Inc.

See all Press Releases

WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14

President and CEO Dr. Chris Savile to provide business update at event open to all investors

Mountain View, California – June 7, 2023 – Willow Biosciences Inc.(“Willow“) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announces that it has been invited to present at the Emerging Growth Conference on June 14.

President and CEO Dr. Chris Savile will participate in a live virtual presentation at 10:15 a.m. Eastern Time and provide an update on Willow’s business. The live presentation is available for all investors.

RSVP: Please register here to ensure you are able to attend the conference and receive any updates on the company that are released.

If attendees are not able to join the live event on June 14, an archived webcast will also be available on the EmergingGrowth.com and on the Emerging Growth YouTube Channel afterward.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

About Willow Biosciences Inc.

Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow’s FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com.

For further information, please contact:

Travis Doupe

Chief Financial Officer

info@willowbio.com

News

Latest news, media & events

18/11/2024

WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERINGTO RAISE UP TO $2.0 MILLION

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
12/11/2024

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Company reports record revenue of $1.7 million in Q3 Company announced a partnership in...
07/11/2024

WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO

Sunnyvale, California – November 7, 2024 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW)...
19/09/2024

WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Rapid success of first program leads to second collaboration to develop optimized enzyme for...
05/09/2024

WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.

The agreement with Kalsec anticipates milestone payments for finalizing research and development work and...
12/08/2024

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Company reports record revenue of $1.0 million, an increase of approximately 600% over the...
07/08/2024

WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY

After a successful feasibility study, Company expands into the high growth biopesticide sector with...
27/07/2024

WILLOW BIOSCIENCES ANNOUNCESANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Sunnyvale, California – July 26, 2024 – Willow Biosciences Inc.("Willow" or the "Company") (TSX: WLLW;...
18/07/2024

WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES Calgary,...
26/06/2024

WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM

Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical...
03/06/2024

WILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERINGTO RAISE UP TO $3.0 MILLION

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
30/05/2024

WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS

Collaboration provides Laurus access to Willow's AI-driven bioengineering platform The strategic alliance includes an...
18/05/2024

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Company continues to advance its corticosteroid production platform and anticipates signing a large strategic...
28/03/2024

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Completed the reorganization of the Company during 2023 with all lab operations now located...
29/02/2024

WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC

Calgary, Alberta – February 29, 2024 – Willow Biosciences Inc.("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF),...
20/02/2024

WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS

Investment further validates Willow’s technology for the development and sustainable manufacture of natural ingredients...
31/01/2024

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Sunnyvale, California – January 31, 2024 – Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a...
16/01/2024

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Sunnyvale, California – January 16, 2024 – Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a...
10/01/2024

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Estimated FY 2023 revenues in excess of $1.3 million is a record year for...
07/12/2023

WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Program brings immediate R&D revenue and first commercial supply revenue as early as 2024...
21/11/2023

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Record revenues for the third quarter and the nine months ended September 30, 2023...
11/10/2023

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING

Calgary, Alberta – October 10, 2023 – Willow Biosciences Inc.("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF),...
03/10/2023

WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION

Sunnyvale, California  ̶  October 3, 2023  ̶ Willow Biosciences Inc., (“Willow”) (TSX: WLLW) (OTCQB:...
12/09/2023

WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING

Calgary, Alberta – September 12, 2023 – Willow Biosciences Inc.("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF),...
06/09/2023

WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA

Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the "Holy Grails" of...
02/09/2023

WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST

Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by...
24/08/2023

WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM

Announces commercial focus on BioOxiTM bio-oxidation platform as part of targeted alignment on nearer-term and...
21/08/2023

WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Sunnyvale, California – August 21, 2023 – Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a...
08/08/2023

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

New partnerships and contracts expected to bring in $1 million in near-term R&D/milestone revenue...
02/08/2023

WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9

President and CEO Dr. Chris Savile to provide business update at event open to...
20/07/2023

WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS

Program further validates Willow’s technology and focus on commercial execution and aligns with its...
07/06/2023

WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14

President and CEO Dr. Chris Savile to provide business update at event open to...
31/05/2023

WILLOW SIGNS MASTER SERVICES AGREEMENT WITH INNOVATIVE BIOTECH COMPANY TO DEVELOP INGREDIENTS FOR AGE-RELATED DISEASES

Biotech partner recognizes strength of Willow’s first in class FutureGrownTM technology platform for producing...
23/05/2023

KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT

Rapid success of first collaboration leads to partnership on high-value specialty ingredient Enzyme development...
15/05/2023

WILLOW BIOSCIENCES ANNOUNCESANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Mountain View, California – May 12, 2023 – Willow Biosciences Inc.("Willow" or the "Company")...
12/05/2023

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS

Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue...
18/04/2023

WILLOW ANNOUNCES COMMERCIAL AGREEMENT WITH SANDHILL ONE

Commercial agreement follows the early success on the development phase of the UDCA program...
12/04/2023

WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING

Complements Company’s significant expertise in existing strain engineering and  precision fermentation Offers commercial partners...
28/03/2023

WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Willow Continues its Transition to the Bay Area in California with Management Promotions and...
22/03/2023

WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY

Calgary, Alberta and Mountain View, California March 22, 2023 - WILLOW BIOSCIENCES, (TSX: WLLW)...
22/03/2023

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILING OF ITS 2022 AIF

Reports Highest Quarterly and Annual Revenue in Company History with Significant Year-Over-Year Growth Expected...
22/02/2023

WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS

Dr. Lalonde has pioneered key advancements in enzyme engineering and biocatalysis that has revolutionized...
17/01/2023

WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT

Represents early progress against targeted milestones anticipated for 2023 to expand company growth Calgary,...
14/12/2022

WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH

Calgary, Alberta and Mountain View, California – December 14, 2022 – Willow Biosciences Inc.("Willow"...
07/12/2022

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Calgary, Alberta and Mountain View, California – December 7, 2022 – Willow Biosciences Inc.("Willow")...
08/11/2022

KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION

Kalamazoo, Michigan, Calgary, Alberta and Mountain View, California – November 8, 2022 – Willow Biosciences...
07/11/2022

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Calgary, Alberta and Mountain View, California – November 7, 2022 – Willow Biosciences Inc. ("Willow" or...
03/11/2022

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO

Calgary, Alberta and Mountain View, California – November 3, 2022 – Willow Biosciences Inc. ("Willow" or...
12/10/2022

WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO

Calgary, Alberta and Mountain View, California – October 12, 2022 – Willow Biosciences Inc. ("Willow" or...
31/08/2022

WILLOW BIOSCIENCES PROVIDES CBG UPDATE

Calgary, Alberta and Mountain View, California – August 31, 2022 – Willow Biosciences Inc. ("Willow"...
15/08/2022

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS

Calgary, Alberta and Mountain View, California – August 15, 2022 – Willow Biosciences Inc. ("Willow" or...
18/07/2022

WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO

Calgary, Alberta and Mountain View, California – July 18, 2022 – Willow Biosciences Inc. ("Willow" or...
06/06/2022

WILLOW BIOSCIENCES INCORPORATES INSCRIPTA’S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT

Calgary, Alberta and Mountain View, California – June 6, 2022 – Willow Biosciences Inc. ("Willow" or...
31/05/2022

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Calgary, Alberta and Mountain View, California – May 31, 2022 – Willow Biosciences Inc. ("Willow"...
12/05/2022

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS

Vancouver, British Columbia – May 12, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
11/05/2022

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION

Vancouver, British Columbia – May 11, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
30/03/2022

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE

Vancouver, British Columbia – March 29, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
31/01/2022

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Vancouver, British Columbia – January 31, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/01/2022

WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE

Vancouver, British Columbia – January 19, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
15/11/2021

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2021 RESULTS

Vancouver, British Columbia – November 15, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
21/09/2021

WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL SCALE OPERATIONAL UPDATE, CBGA PRODUCTION UPDATE AND CORPORATE UPDATE

Vancouver, British Columbia – September 21, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
09/08/2021

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2021 RESULTS

Vancouver, British Columbia – August 9, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
20/07/2021

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS COMMERCIAL OPERATIONS TEAM AND DEVELOPMENT PORTFOLIO, AN UPDATE ON ITS INTELLECTUAL PROPERTY POSITION, AND FORMATION OF ESG COMMITTEE

ancouver, British Columbia – July 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
10/06/2021

WILLOW BIOSCIENCES AND CELLULAR GOODS ANNOUNCE MULTIYEAR SUPPLY AGREEMENT FOR CANNABIGEROL (CBG)

Vancouver, British Columbia – June 10, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
25/05/2021

WILLOW BIOSCIENCES ANNOUNCES PARTICIPATION IN SYNBIOBETA PANEL DISCUSSION

Vancouver, British Columbia – May 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
18/05/2021

WILLOW BIOSCIENCES ADDED TO NYSE-LISTED CANNABIS ETF “THCX”

Vancouver, British Columbia – May 18, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
07/05/2021

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2021 RESULTS, AN OPERATIONAL UPDATE AND THE ADDITION OF A NEW BOARD MEMBER

Vancouver, British Columbia – May 7, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
28/04/2021

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Vancouver, British Columbia – April 28, 2021 – Willow Biosciences Inc. ("Willow" or "the Company")...
20/04/2021

WILLOW BIOSCIENCES ANNOUNCES GROUND-BREAKING SCIENTIFIC DATA FOR CANNABIGEROL (CBG) ON HUMAN SKIN

Vancouver, British Columbia – April 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
31/03/2021

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF ITS FIRST COMMERCIAL SCALE FERMENTATION RUN

Vancouver, British Columbia – March 31, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
24/03/2021

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2020 YEAR END RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – March 23, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
03/03/2021

WILLOW BIOSCIENCES PROVIDES UPDATE ON ACCELERATION OF EXPIRY DATE OF OUTSTANDING WARRANTS ISSUED PURSUANT TO OCTOBER 2020 UNIT FINANCING

Vancouver, British Columbia – March 3, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/02/2021

WILLOW BIOSCIENCES ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION AND COMPLETION OF PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING

Vancouver, British Columbia – February 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
11/02/2021

WILLOW BIOSCIENCES ANNOUNCES INCREASE TO BOUGHT DEAL OFFERING FROM $20.0 MILLION TO $25.0 MILLION

Vancouver, British Columbia – Feb. 11, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
26/01/2021

WILLOW BIOSCIENCES ANNOUNCES ACCELERATION OF EXPIRY DATE OF OUTSTANDING WARRANTS ISSUED PURSUANT TO OCTOBER 2020 UNIT FINANCING

Vancouver, British Columbia – January 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/01/2021

WILLOW BIOSCIENCES ADVANCES ITS WORK ON THC; PLANS TO LAUNCH IN THE CANADIAN MARKET

Vancouver, British Columbia – January 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
13/01/2021

WILLOW BIOSCIENCES PROVIDES UPDATE ON CANNABIGEROL RESEARCH STUDIES AND KEY PERSONNEL APPOINTMENT

Vancouver, British Columbia – January 13, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
16/12/2020

WILLOW BIOSCIENCES ADVANCES ITS COMMERICALIZATION PLAN; FIRST COMMERCIAL PRODUCTION EXPECTED IN EARLY 2021

Leading manufacturer contracted for commercial cannabinoid production • First commercial quantities of ultra-pure CBG...
13/11/2020

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2020 RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – November 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
21/10/2020

WILLOW BIOSCIENCES ANNOUNCES PRICING AND UPSIZE OF PREVIOUSLY ANNOUNCED PUBLIC OFFERING TO $10.0 MILLION

Vancouver, British Columbia – October 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
20/10/2020

WILLOW BIOSCIENCES ANNOUNCES OVERNIGHT MARKETED PUBLIC OFFERING FOR PROCEEDS OF APPROXIMATELY $8.0 MILLION

Vancouver, British Columbia – October 20, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
08/10/2020

WILLOW BIOSCIENCES PARTNERS WITH RESEARCHERS AT THE UNIVERSITY OF LETHBRIDGE AND UNIVERSITY OF CALGARY TO STUDY EFFECTS OF NON-PSYCHOACTIVE CANNABINOIDS ON PAIN, INFLAMMATION AND DEPRESSION

Vancouver, British Columbia – October 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
21/09/2020

WILLOW BIOSCIENCES ANNOUNCES SUCCESSFUL PRODUCTION OF PURE CANNABIGEROL

Vancouver, British Columbia – Sept 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
08/09/2020

WILLOW BIOSCIENCES ANNOUNCES RESEARCH AND DEVELOPMENT FUNDING FOR ITS VARIN CANNABINOIDS

Vancouver, British Columbia – September 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
12/08/2020

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2020 RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – August 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
29/07/2020

WILLOW BIOSCIENCES ANNOUNCES IT HAS COMMENCED ITS PILOT TO PRODUCE ITS FIRST CANNABINOID

Vancouver, British Columbia – July 29, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
06/07/2020

Willow Biosciences Inc. to Webcast Live at VirtualInvestorConferences.com July 9th

Company invites individual and institutional investors, as well as advisors and analysts, to attend...
22/06/2020

WILLOW BIOSCIENCES ANNOUNCES APPOINTMENT OF SENIOR VICE PRESIDENT, SALES AND MARKETING

Calgary, Alberta – June 22, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
17/06/2020

WILLOW BIOSCIENCES ANNOUNCES EXPEDITED PILOT PRODUCTION AND ADDS MULTIPLE NEW CANNABINOIDS TO PORTFOLIO

Calgary, Alberta – June 17, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
14/05/2020

Willow Biosciences Reports First Quarter 2020 Results and Provides Operations Update

Calgary, Alberta – May 14, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
09/04/2020

Willow Biosciences Announces Changes To Its Management Team

Calgary, Alberta – April 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
24/03/2020

Willow Biosciences Reports Fourth Quarter And 2019 Year End Results And Operational Update

Calgary, Alberta – March 24, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
12/03/2020

Willow Biosciences Announces Cannabinoid Scale-up And Expedited Path To Commercialization

Calgary, Alberta – March 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
07/02/2020

Willow Biosciences Improves Governance With Appointment Of Independent Chairman

Calgary, Alberta – February 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
03/12/2019

Willow Biosciences Comments on Descheduling of Partner’s Cannabidiol by U.S. Drug Enforcement Agency

Calgary, Alberta, December 3, 2019 – Willow Biosciences Inc.("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF),...
25/11/2019

Willow Biosciences Receives Conditional Approval to List on the Toronto Stock Exchange

CALGARY, November 25, 2019 – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW;...
21/11/2019

Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update

CALGARY, Nov. 21, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE:...
05/11/2019

Willow Biosciences To Commence Trading on The OTCQB® Venture Market

CALGARY, Alberta, November 5, 2019 — Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:WLLW;...
29/08/2019

Willow Biosciences Reports Second Quarter 2019 Results And Provides Operations Update

Calgary, Alberta – August 29, 2019 – Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:...
04/06/2019

Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol

New activity will add options and potential for cost savings to Noramco’s robust CBD...
27/05/2019

Willow Biosciences and Tuatara Capital Announce Exercise of Warrants

CALGARY, May 27, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE:...
14/05/2019

Willow Biosciences Inc. Announces Share Consolidation

CALGARY, May 14, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW)...
12/04/2019

Makena Resources Inc., Biocan Technologies Inc. and Epimeron Inc. Announce Completion of Private Placement, Strategic Investment From Tuatara Capital and Business Combination to Form Willow Biosciences Inc.

VANCOUVER and CALGARY, April 12, 2019 /CNW/ – Makena Resources Inc. (“Makena“) (CSE: MKNA),...
Get Willow updates
Contact

Phone: +1 403 910 5140
Email: info@willowbio.com

Willow Biosciences white W logo.

© 2023 Willow Biosciences Inc.
Powered by BragDeal Inc.

Follow us

Mountain View, CA

Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.